公开(公告)号：WO2012000103A1

公开(公告)日：2012-01-05

申请号：PCT/CA2011000776

申请日：2011-07-04

Applicant: UNIV HEALTH NETWORK ,  PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

Inventor： PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation, hi particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

Abstract translation: 本文提供用于治疗癌症患者的方法，用途和组合物，其中癌症的特征在于PTEN基因突变。在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物，以及鉴定 如果存在PTEN基因突变，则可能对PLK4拮抗剂治疗有反应的患者。

公开(公告)号：EP2588110A4

公开(公告)日：2014-04-16

申请号：EP11800027

申请日：2011-07-04

Applicant: UNIV HEALTH NETWORK

Inventor： PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：AU2018328773B2

公开(公告)日：2023-11-16

申请号：AU2018328773

申请日：2018-09-07

Applicant: UNIV HEALTH NETWORK

Inventor： MASON JACQUELINE M ,  BRAY MARK R ,  MAK TAK WAH ,  FLETCHER GRAHAM

IPC: C07D413/10 ,  A61K31/5377 ,  A61K39/395 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：CA2803446C

公开(公告)日：2019-06-04

申请号：CA2803446

申请日：2011-07-04

Applicant: UNIV HEALTH NETWORK

Inventor： PAN GUOHUA ,  MASON JACQUELINE M ,  WEI XIN ,  FEHER MIKLOS

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：AU2014336917A1

公开(公告)日：2016-05-05

申请号：AU2014336917

申请日：2014-10-03

Applicant: UNIV HEALTH NETWORK

Inventor： HEDLEY DAVID W ,  LOHSE INES ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: C07D413/14 ,  A61K31/416 ,  A61K31/5377 ,  A61P35/00

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

公开(公告)号：CA2927612A1

公开(公告)日：2015-04-23

申请号：CA2927612

申请日：2014-10-03

Applicant: UNIV HEALTH NETWORK

Inventor： HEDLEY DAVID W ,  LOHSE INES ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP3212652A4

公开(公告)日：2018-04-25

申请号：EP15855932

申请日：2015-10-09

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  BROKX RICHARD ,  PAULS HEINZ W ,  LI SZE-WAN ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

公开(公告)号：EP3057593A4

公开(公告)日：2017-03-08

申请号：EP14853347

申请日：2014-10-03

Applicant: UNIV HEALTH NETWORK

Inventor： HEDLEY DAVID W ,  LOHSE INES ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  C07D403/08 ,  C07D413/14 ,  A61K2300/00

公开(公告)号：CA3242099A1

公开(公告)日：2023-06-29

申请号：CA3242099

申请日：2022-12-21

Applicant: UNIV HEALTH NETWORK

Inventor： BRAY MARK R ,  MASON JACQUELINE M ,  WEI XIN ,  DUNCAN GORDON

IPC: A61K31/437 ,  A61P35/02 ,  C07D471/04

Abstract: The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma by administration of Compound (I), or a pharmaceutically acceptable salt thereof.

公开(公告)号：CA2927612C

公开(公告)日：2022-08-30

申请号：CA2927612

申请日：2014-10-03

Applicant: UNIV HEALTH NETWORK

Inventor： HEDLEY DAVID W ,  LOHSE INES ,  MASON JACQUELINE M ,  BRAY MARK R

IPC: A61K31/5377 ,  A61K31/416 ,  A61P35/00 ,  C07D413/14

Abstract: The invention is related to a method of treating a subject with pancreatic cancer with administration of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof.